Impact of Clinical Pharmacy Services Provided for Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

Official title:

Impact of Clinical Pharmacy Services Provided for Patients With Active Rheumatoid Arthritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03743181
• Other study ID #: 156
• Status: Completed
• Start date: January 14, 2018
• Est. completion date: December 18, 2019

Study information

• Verified date: January 2020
• Source: Ain Shams University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Enrolment of clinical pharmacy services in RA patients as a part of health care system has been investigated at many studies but not investigated in active RA patients before. This study aimed to detect drug therapy-related problems (DTRPs) in active rheumatoid arthritis (RA) patients and Investigate the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life (QoL). Methods:Prospective, randomized controlled study to be carried out at rheumatology outpatient clinic, Ain Shams University Hospitals on 50 patients with active RA for 6 months.determine if any drug therapy problems are present.Develop a plan of care that includes interventions to resolve drug therapy problems, achieve goals of therapy, and prevent drug therapy problems. questionnaires was used to measure functional status in RA patients using health assessment questionnaire (HAQ) and assess self-reported quality of life in patients with (RA) using rheumatoid arthritis quality of life questionnaire (RAQOL) and measure adherence using the 4-item Morisky Green Levine Medication Adherence Scale and Disease Activity Score-28 was used as an objective method to assess RA disease activity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: December 18, 2019
• Est. primary completion date: October 10, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Patients aged 18-60 years old

• fulfillment of the American College of Rheumatology /European league against rheumatism (2010 ACR/EULAR ) diagnostic criteria for RA.

• patients with active RA(defined by DAS28 score < 5.1)

Exclusion Criteria:

• Patients with cognitive impairment.

• The presence of hepatic or renal disease.

• The presence of other rheumatic and connective tissue disorders.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Other:
• pharmaceutical care services
detection of drug therapy problems and investigation of the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life

Locations

Country	Name	City	State
Egypt	Facuty of Pharmacu Ain Shams University	Cairo	Abasiya

Sponsors (1)

Lead Sponsor	Collaborator
hager omar mohammed siddik

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	disease activity score	disease activity score-28 (DAS-28) for measuring disease activity in rheumatoid arthritis patients	6 months
Primary	Quality of life questionnaire	Rheumatoid arthritis quality of life questionnaire (RAQOL) for measuring quality of life	6 months
Primary	Health assessment questionnaire	Health assessment questionnaire (HAQ) for measuring functional status in rheumatoid arthritis patients	6 months